Table 1 Adverse events in each of the hormonal therapies and orchiectomy groups.

From: A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials

Orchiectomy (%)

Antiandrogen (%)

LHRH (%)

LHRH plus Antiandrogen (%)

Vasodilation (8.3)

Male breast pain (7.1)

Gynecomastia (6.9)

Headache (5.5)

Gynecomastia (8.3)

Impotence (3.6)

Vasodilation (4.9)

Gynecomastia (4.5)

Nausea (6.3)

Rash (2.9)

Male breast pain (4.3)

Asthenia (4.2)

Rash (4.2)

 

Breast tenderness (3.6)

Vasodilation (3.9)

Face edema (4.2)

 

Hot flashes (3.3)

Rash (3.2)

Nipple tenderness (4.2)

 

Nausea (3)

Peripheral oedema (2.9)

Breast tenderness (4.2)

 

Impotence (3)

Diarrhea (2.6)

  

Diarrhea (2.6)

Constipation (2.6)

   

Rhinitis (2.6)

  1. Adverse events (COSTART coding symbol terms and MedDRA terms) reported as caused by the treatment and by at least 2.5% of the subjects (percentage given in parentheses) in each of the groups are listed. Similar terms from the different vocabularies were manually merged.